Workman P - Search Results

1

Polypharmacology in Precision Oncology: Current Applications and Future Prospects.

Antolin AA, Workman P, Mestres J, Al-Lazikani B. Antolin AA, et al. Among authors: workman p. Curr Pharm Des. 2016;22(46):6935-6945. doi: 10.2174/1381612822666160923115828. Curr Pharm Des. 2016. PMID: 27669965 Free PMC article. Review.

2

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development.

Workman P. Workman P. Curr Pharm Des. 2003;9(11):891-902. doi: 10.2174/1381612033455279. Curr Pharm Des. 2003. PMID: 12678873 Review.

3

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.

Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P. Tan DS, et al. Among authors: workman p. Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445. Cancer J. 2009. PMID: 19826361 Review.

4

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. Suwaki N, et al. Among authors: workman p. Sci Transl Med. 2011 Jun 1;3(85):85ra47. doi: 10.1126/scitranslmed.3002004. Sci Transl Med. 2011. PMID: 21632985 Free PMC article.

5

Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

Yap TA, Workman P. Yap TA, et al. Among authors: workman p. Annu Rev Pharmacol Toxicol. 2012;52:549-73. doi: 10.1146/annurev-pharmtox-010611-134532. Annu Rev Pharmacol Toxicol. 2012. PMID: 22235862 Review.

6

Discovery of small molecule cancer drugs: successes, challenges and opportunities.

Hoelder S, Clarke PA, Workman P. Hoelder S, et al. Among authors: workman p. Mol Oncol. 2012 Apr;6(2):155-76. doi: 10.1016/j.molonc.2012.02.004. Epub 2012 Mar 3. Mol Oncol. 2012. PMID: 22440008 Free PMC article. Review.

7

Personalized medicine: patient-predictive panel power.

Workman P, Clarke PA, Al-Lazikani B. Workman P, et al. Cancer Cell. 2012 Apr 17;21(4):455-8. doi: 10.1016/j.ccr.2012.03.030. Cancer Cell. 2012. PMID: 22516256 Free article.

8

Combinatorial drug therapy for cancer in the post-genomic era.

Al-Lazikani B, Banerji U, Workman P. Al-Lazikani B, et al. Among authors: workman p. Nat Biotechnol. 2012 Jul 10;30(7):679-92. doi: 10.1038/nbt.2284. Nat Biotechnol. 2012. PMID: 22781697 Review.

9

Objective assessment of cancer genes for drug discovery.

Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Patel MN, et al. Among authors: workman p. Nat Rev Drug Discov. 2013 Jan;12(1):35-50. doi: 10.1038/nrd3913. Nat Rev Drug Discov. 2013. PMID: 23274470 Review.

10

Unpicking the combination lock for mutant BRAF and RAS melanomas.

Al-Lazikani B, Workman P. Al-Lazikani B, et al. Among authors: workman p. Cancer Discov. 2013 Jan;3(1):14-9. doi: 10.1158/2159-8290.CD-12-0520. Cancer Discov. 2013. PMID: 23319765

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

603 results

Search Page